Subject : A multicentric, cross-sectional, observational survey study to understand the role of Bromfenac 0.09% eye drops in management of inflammation and pain after cataract surgery
Ocular inflammation is common after cataract surgery. Complications resulting from inflammation include increased intraocular pressure, posterior capsular opacification, cystoid macular edema, and decreased visual acuity. Topical NSAIDs are widely used and they reduce inflammation by inhibiting prostaglandin synthesis. They have been shown to be clinically effective in controlling inflammation after cataract surgery. Bromfenac is an effective cyclooxygenase 1 and cyclooxygenase 2 inhibitor. Bromfenac 0.09% is indicated for the treatment of pain and inflammation associated with cataract surgery.
Bromfenac 0.09% eye drops is marketed by the Avesta team of Sun Pharma as ‘Megabrom’.
This multicentric, cross-sectional observational survey study is planned to understand the role of Bromfenac 0.09% eye drops in management of post op inflammation and pain after cataract surgery.
We invite you to participate in this study and share your experience through a cross-sectional surey, thus, it is not an experimental/interventional study.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit, we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}